Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a
CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic
sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.